What is Zacks Research’s Forecast for Teleflex Q3 Earnings?

Teleflex Incorporated (NYSE:TFX) – Investment analysts at Zacks Research cut their Q3 2025 earnings per share estimates for shares of Teleflex in a research note issued on Wednesday, October 23rd. Zacks Research analyst R. Department now expects that the medical technology company will post earnings of $3.88 per share for the quarter, down from their previous forecast of $3.90. The consensus estimate for Teleflex’s current full-year earnings is $13.97 per share. Zacks Research also issued estimates for Teleflex’s FY2025 earnings at $15.34 EPS, Q2 2026 earnings at $4.13 EPS and FY2026 earnings at $16.75 EPS.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.33 by $0.09. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The firm had revenue of $749.70 million during the quarter, compared to analysts’ expectations of $762.98 million. During the same period in the previous year, the company earned $3.41 earnings per share. The company’s revenue was up .9% compared to the same quarter last year.

TFX has been the topic of several other reports. Truist Financial raised their target price on Teleflex from $247.00 to $255.00 and gave the company a “hold” rating in a report on Monday, October 14th. Stephens raised their price objective on Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Royal Bank of Canada boosted their target price on Teleflex from $260.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and increased their price target for the company from $205.00 to $245.00 in a report on Monday, July 1st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Teleflex presently has a consensus rating of “Moderate Buy” and a consensus target price of $268.86.

Teleflex Stock Down 0.9 %

TFX stock opened at $235.62 on Friday. The firm has a market cap of $11.10 billion, a PE ratio of 42.30, a PEG ratio of 2.15 and a beta of 1.16. Teleflex has a 1 year low of $177.63 and a 1 year high of $257.85. The company has a fifty day simple moving average of $241.19 and a 200 day simple moving average of $223.48. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were given a $0.34 dividend. The ex-dividend date was Thursday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.58%. Teleflex’s dividend payout ratio is 24.42%.

Insider Transactions at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the transaction, the director now directly owns 5,496 shares in the company, valued at $1,313,159.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.43% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Teleflex by 1.8% in the first quarter. Vanguard Group Inc. now owns 5,550,727 shares of the medical technology company’s stock valued at $1,255,408,000 after buying an additional 96,711 shares during the period. Janus Henderson Group PLC raised its holdings in Teleflex by 12.0% in the 1st quarter. Janus Henderson Group PLC now owns 5,409,317 shares of the medical technology company’s stock valued at $1,223,424,000 after acquiring an additional 581,312 shares in the last quarter. Cooke & Bieler LP lifted its position in shares of Teleflex by 23.3% in the 2nd quarter. Cooke & Bieler LP now owns 912,797 shares of the medical technology company’s stock worth $191,989,000 after acquiring an additional 172,335 shares during the period. TD Asset Management Inc grew its holdings in shares of Teleflex by 12.0% during the 2nd quarter. TD Asset Management Inc now owns 456,081 shares of the medical technology company’s stock worth $95,928,000 after purchasing an additional 48,832 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Teleflex by 6.6% during the second quarter. Bank of New York Mellon Corp now owns 425,647 shares of the medical technology company’s stock valued at $89,526,000 after purchasing an additional 26,325 shares during the period. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.